2,582 Shares in Hologic, Inc. (NASDAQ:HOLX) Bought by Cassaday & Co Wealth Management LLC

Cassaday & Co Wealth Management LLC purchased a new position in Hologic, Inc. (NASDAQ:HOLX) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 2,582 shares of the medical equipment provider’s stock, valued at approximately $210,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Cetera Investment Advisers boosted its stake in Hologic by 188.9% during the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after buying an additional 13,380 shares during the last quarter. Clearbridge Investments LLC raised its position in shares of Hologic by 51.4% during the 1st quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock valued at $40,430,000 after buying an additional 176,006 shares in the last quarter. Andra AP fonden grew its position in Hologic by 224.5% in the second quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock worth $7,083,000 after acquiring an additional 66,000 shares in the last quarter. Swedbank AB increased its stake in Hologic by 5.2% during the second quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider’s stock worth $121,060,000 after acquiring an additional 80,575 shares during the last quarter. Finally, National Bank of Canada FI boosted its holdings in shares of Hologic by 352.0% in the 1st quarter. National Bank of Canada FI now owns 299,098 shares of the medical equipment provider’s stock worth $22,474,000 after purchasing an additional 232,928 shares during the period. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the subject of a number of analyst reports. Stephens restated an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Leerink Partners cut their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Tuesday, October 15th. UBS Group upped their target price on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, Raymond James raised their price target on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Hologic has an average rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Trading Up 0.2 %

NASDAQ:HOLX opened at $78.79 on Tuesday. The firm has a 50-day simple moving average of $80.63 and a 200-day simple moving average of $78.28. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67. The firm has a market cap of $18.30 billion, a P/E ratio of 23.66, a P/E/G ratio of 2.48 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter in the previous year, the firm posted $0.89 earnings per share. Hologic’s revenue for the quarter was up 4.5% compared to the same quarter last year. Equities analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.